Clinical trial · Observational
The Osteosarcoma Biobank in Peking University People's Hospital
Establishment of Osteosarcoma Biobank
NCT03362086CI-TRIAL-00030682unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Osteosarcoma is very rare bone tumor. The investigator set up the biobank to ensure the patients has the chance to participate in future research
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteosarcoma | Osteosarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Examine VEGFR-2 and PD-L1 gene expression osteosarcoma
- timeFrame
- 3 years
- description
- To examine the VEGFR2 and programmed cell death ligand 1 (PD-L1) genes expression of the patients with osteosarcoma.And Analyze their differences.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Proband Inclusion criteria: A diagnosis or suspected diagnosis of osteosarcoma Exclusion Criteria: non-asian pulmonary metastasis
References
Publications (0)
Data not yet available
No reference posted for this study.